The Catalyst https://catalyst.phrma.org We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you. en-us Fri, 09 Dec 2022 14:30:01 GMT 2022-12-09T14:30:01Z en-us ICYMI: PhRMA COO Lori Reilly speaks about the health care agenda for the next Congress https://catalyst.phrma.org/icymi-phrma-coo-lori-reilly-speaks-about-the-health-care-agenda-for-the-next-congress <div class="hs-featured-image-wrapper"> <a href="https://catalyst.phrma.org/icymi-phrma-coo-lori-reilly-speaks-about-the-health-care-agenda-for-the-next-congress" title="" class="hs-featured-image-link"> <img src="https://catalyst.phrma.org/hubfs/Cardiac%20Care%20%2843%29.png" alt="ICYMI: PhRMA COO Lori Reilly speaks about the health care agenda for the next Congress" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"> </a> </div> <p>With a divided Congress, bipartisan action will be necessary to move the needle on health care policy. On December 7, 2022, PhRMA sponsored the Axios event, “<a href="https://www.axios.com/2022/11/18/axios-event-senator-hickenlooper-health-policy-midterms">The Post-Midterm Health Care Agenda</a>,” where I participated in a View from the Top segment with Nicholas Johnston, publisher of Axios. We discussed PhRMA’s focus on passing the PASTEUR Act in the last few weeks of 2022, and laid out PhRMA’s priorities heading into 2023 that will support and protect patients.</p> <div class="hs-featured-image-wrapper"> <a href="https://catalyst.phrma.org/icymi-phrma-coo-lori-reilly-speaks-about-the-health-care-agenda-for-the-next-congress" title="" class="hs-featured-image-link"> <img src="https://catalyst.phrma.org/hubfs/Cardiac%20Care%20%2843%29.png" alt="ICYMI: PhRMA COO Lori Reilly speaks about the health care agenda for the next Congress" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"> </a> </div> <p>With a divided Congress, bipartisan action will be necessary to move the needle on health care policy. On December 7, 2022, PhRMA sponsored the Axios event, “<a href="https://www.axios.com/2022/11/18/axios-event-senator-hickenlooper-health-policy-midterms">The Post-Midterm Health Care Agenda</a>,” where I participated in a View from the Top segment with Nicholas Johnston, publisher of Axios. We discussed PhRMA’s focus on passing the PASTEUR Act in the last few weeks of 2022, and laid out PhRMA’s priorities heading into 2023 that will support and protect patients.</p> <img src="https://track.hubspot.com/__ptq.gif?a=464546&amp;k=14&amp;r=https%3A%2F%2Fcatalyst.phrma.org%2Ficymi-phrma-coo-lori-reilly-speaks-about-the-health-care-agenda-for-the-next-congress&amp;bu=https%253A%252F%252Fcatalyst.phrma.org&amp;bvt=rss" alt="" width="1" height="1" style="min-height:1px!important;width:1px!important;border-width:0!important;margin-top:0!important;margin-bottom:0!important;margin-right:0!important;margin-left:0!important;padding-top:0!important;padding-bottom:0!important;padding-right:0!important;padding-left:0!important; "> Health Insurance Pharmacy Benefit Managers Policy Solutions Antimicrobial Resistance Government Price Setting Fri, 09 Dec 2022 14:30:00 GMT https://catalyst.phrma.org/icymi-phrma-coo-lori-reilly-speaks-about-the-health-care-agenda-for-the-next-congress 2022-12-09T14:30:00Z Lori Reilly Sparking conversations — and careers — at the 2nd annual Pathways to Success Summit https://catalyst.phrma.org/sparking-conversations-and-careers-at-the-2nd-annual-pathways-to-success-summit <div class="hs-featured-image-wrapper"> <a href="https://catalyst.phrma.org/sparking-conversations-and-careers-at-the-2nd-annual-pathways-to-success-summit" title="" class="hs-featured-image-link"> <img src="https://catalyst.phrma.org/hubfs/GradSummitRecapBlog_Thumbnail.jpg" alt="Sparking conversations — and careers — at the 2nd annual Pathways to Success Summit" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"> </a> </div> <p>On September 28-29, 2022, PhRMA hosted the second annual Pathways to Success: Virtual Graduate Summit and Career Expo. This event provided a unique opportunity for students and faculty from diverse backgrounds to engage with biopharma recruiters and employees. For the second year in a row, our attendees discovered career opportunities and built connections in the biopharma industry, all while learning valuable knowledge from mentors and thought leaders.</p> <div class="hs-featured-image-wrapper"> <a href="https://catalyst.phrma.org/sparking-conversations-and-careers-at-the-2nd-annual-pathways-to-success-summit" title="" class="hs-featured-image-link"> <img src="https://catalyst.phrma.org/hubfs/GradSummitRecapBlog_Thumbnail.jpg" alt="Sparking conversations — and careers — at the 2nd annual Pathways to Success Summit" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"> </a> </div> <p>On September 28-29, 2022, PhRMA hosted the second annual Pathways to Success: Virtual Graduate Summit and Career Expo. This event provided a unique opportunity for students and faculty from diverse backgrounds to engage with biopharma recruiters and employees. For the second year in a row, our attendees discovered career opportunities and built connections in the biopharma industry, all while learning valuable knowledge from mentors and thought leaders.</p> <img src="https://track.hubspot.com/__ptq.gif?a=464546&amp;k=14&amp;r=https%3A%2F%2Fcatalyst.phrma.org%2Fsparking-conversations-and-careers-at-the-2nd-annual-pathways-to-success-summit&amp;bu=https%253A%252F%252Fcatalyst.phrma.org&amp;bvt=rss" alt="" width="1" height="1" style="min-height:1px!important;width:1px!important;border-width:0!important;margin-top:0!important;margin-bottom:0!important;margin-right:0!important;margin-left:0!important;padding-top:0!important;padding-bottom:0!important;padding-right:0!important;padding-left:0!important; "> PhRMA Member Company Equity Thu, 08 Dec 2022 20:00:00 GMT https://catalyst.phrma.org/sparking-conversations-and-careers-at-the-2nd-annual-pathways-to-success-summit 2022-12-08T20:00:00Z Dr. Steven Thomas In their own words: Financial barriers exacerbate access challenges for insured Americans https://catalyst.phrma.org/in-their-own-words-financial-barriers-exacerbate-access-challenges-for-insured-americans <div class="hs-featured-image-wrapper"> <a href="https://catalyst.phrma.org/in-their-own-words-financial-barriers-exacerbate-access-challenges-for-insured-americans" title="" class="hs-featured-image-link"> <img src="https://catalyst.phrma.org/hubfs/Cardiac%20Care%20%2811%29.png" alt="In their own words: Financial barriers exacerbate access challenges for insured Americans" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"> </a> </div> <p>A survey of more than 5,000 Americans conducted with Ipsos found that 30% of insured Americans say they face a financial barrier to care, such as unaffordable out-of-pocket costs or a lack of savings to pay for emergency or unforeseen expenses.</p> <div class="hs-featured-image-wrapper"> <a href="https://catalyst.phrma.org/in-their-own-words-financial-barriers-exacerbate-access-challenges-for-insured-americans" title="" class="hs-featured-image-link"> <img src="https://catalyst.phrma.org/hubfs/Cardiac%20Care%20%2811%29.png" alt="In their own words: Financial barriers exacerbate access challenges for insured Americans" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"> </a> </div> <p>A survey of more than 5,000 Americans conducted with Ipsos found that 30% of insured Americans say they face a financial barrier to care, such as unaffordable out-of-pocket costs or a lack of savings to pay for emergency or unforeseen expenses.</p> <img src="https://track.hubspot.com/__ptq.gif?a=464546&amp;k=14&amp;r=https%3A%2F%2Fcatalyst.phrma.org%2Fin-their-own-words-financial-barriers-exacerbate-access-challenges-for-insured-americans&amp;bu=https%253A%252F%252Fcatalyst.phrma.org&amp;bvt=rss" alt="" width="1" height="1" style="min-height:1px!important;width:1px!important;border-width:0!important;margin-top:0!important;margin-bottom:0!important;margin-right:0!important;margin-left:0!important;padding-top:0!important;padding-bottom:0!important;padding-right:0!important;padding-left:0!important; "> Health Insurance Out-of-Pocket Costs Pharmacy Benefit Managers Polling Thu, 08 Dec 2022 14:14:23 GMT https://catalyst.phrma.org/in-their-own-words-financial-barriers-exacerbate-access-challenges-for-insured-americans 2022-12-08T14:14:23Z Tom Wilbur Traditional HTAs keep diverse patients out of the conversation https://catalyst.phrma.org/traditional-htas-keep-diverse-patients-out-of-the-conversation <div class="hs-featured-image-wrapper"> <a href="https://catalyst.phrma.org/traditional-htas-keep-diverse-patients-out-of-the-conversation" title="" class="hs-featured-image-link"> <img src="https://catalyst.phrma.org/hubfs/Cardiac%20Care%20%2818%29.png" alt="Traditional HTAs keep diverse patients out of the conversation" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"> </a> </div> <p><em>Concerns about the cost of health care have led to calls for the use of health technology assessments or HTAs by the federal government. This would allow government agencies to make important decisions about patient access to health care based on their determination of the value of new tests and treatments. In <a href="https://catalyst.phrma.org/topic/value-assessment">this series</a>, we explore some of the key short-comings of traditional HTA, particularly how it:</em></p> <div class="hs-featured-image-wrapper"> <a href="https://catalyst.phrma.org/traditional-htas-keep-diverse-patients-out-of-the-conversation" title="" class="hs-featured-image-link"> <img src="https://catalyst.phrma.org/hubfs/Cardiac%20Care%20%2818%29.png" alt="Traditional HTAs keep diverse patients out of the conversation" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"> </a> </div> <p><em>Concerns about the cost of health care have led to calls for the use of health technology assessments or HTAs by the federal government. This would allow government agencies to make important decisions about patient access to health care based on their determination of the value of new tests and treatments. In <a href="https://catalyst.phrma.org/topic/value-assessment">this series</a>, we explore some of the key short-comings of traditional HTA, particularly how it:</em></p> <img src="https://track.hubspot.com/__ptq.gif?a=464546&amp;k=14&amp;r=https%3A%2F%2Fcatalyst.phrma.org%2Ftraditional-htas-keep-diverse-patients-out-of-the-conversation&amp;bu=https%253A%252F%252Fcatalyst.phrma.org&amp;bvt=rss" alt="" width="1" height="1" style="min-height:1px!important;width:1px!important;border-width:0!important;margin-top:0!important;margin-bottom:0!important;margin-right:0!important;margin-left:0!important;padding-top:0!important;padding-bottom:0!important;padding-right:0!important;padding-left:0!important; "> Value Assessment Health Equity Wed, 07 Dec 2022 17:00:00 GMT https://catalyst.phrma.org/traditional-htas-keep-diverse-patients-out-of-the-conversation 2022-12-07T17:00:00Z Katie Koziara Stories from the lab: Researchers discuss innovative treatments for cancers of the blood https://catalyst.phrma.org/stories-from-the-lab-researchers-discuss-innovative-treatments-for-cancers-of-the-blood <div class="hs-featured-image-wrapper"> <a href="https://catalyst.phrma.org/stories-from-the-lab-researchers-discuss-innovative-treatments-for-cancers-of-the-blood" title="" class="hs-featured-image-link"> <img src="https://catalyst.phrma.org/hubfs/GettyImages-961012744%20resized.jpg" alt="Stories from the lab: Researchers discuss innovative treatments for cancers of the blood" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"> </a> </div> <p>The biopharmaceutical industry is one of the most research-intensive of all sectors in the U.S. economy and supports a <a href="https://phrma.org/stem">broad range of STEM jobs</a> through R&amp;D and manufacturing. At the backbone of the biopharmaceutical ecosystem are its researchers. Each day, in labs across the country, these individuals work tirelessly on the front lines of research and development to help bring novel medicines to patients. This challenge is far from easy. More often than not, the process of researching and developing innovative treatments is fraught with more setbacks than successes. Despite this, hearing first-hand testimonies from researchers on the successes and future of innovative medicines delivers a sense of hope for patients around the globe.</p> <div class="hs-featured-image-wrapper"> <a href="https://catalyst.phrma.org/stories-from-the-lab-researchers-discuss-innovative-treatments-for-cancers-of-the-blood" title="" class="hs-featured-image-link"> <img src="https://catalyst.phrma.org/hubfs/GettyImages-961012744%20resized.jpg" alt="Stories from the lab: Researchers discuss innovative treatments for cancers of the blood" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"> </a> </div> <p>The biopharmaceutical industry is one of the most research-intensive of all sectors in the U.S. economy and supports a <a href="https://phrma.org/stem">broad range of STEM jobs</a> through R&amp;D and manufacturing. At the backbone of the biopharmaceutical ecosystem are its researchers. Each day, in labs across the country, these individuals work tirelessly on the front lines of research and development to help bring novel medicines to patients. This challenge is far from easy. More often than not, the process of researching and developing innovative treatments is fraught with more setbacks than successes. Despite this, hearing first-hand testimonies from researchers on the successes and future of innovative medicines delivers a sense of hope for patients around the globe.</p> <img src="https://track.hubspot.com/__ptq.gif?a=464546&amp;k=14&amp;r=https%3A%2F%2Fcatalyst.phrma.org%2Fstories-from-the-lab-researchers-discuss-innovative-treatments-for-cancers-of-the-blood&amp;bu=https%253A%252F%252Fcatalyst.phrma.org&amp;bvt=rss" alt="" width="1" height="1" style="min-height:1px!important;width:1px!important;border-width:0!important;margin-top:0!important;margin-bottom:0!important;margin-right:0!important;margin-left:0!important;padding-top:0!important;padding-bottom:0!important;padding-right:0!important;padding-left:0!important; "> Medicines in Development Research and Development PhRMA Member Company Cancer Thu, 01 Dec 2022 15:35:00 GMT https://catalyst.phrma.org/stories-from-the-lab-researchers-discuss-innovative-treatments-for-cancers-of-the-blood 2022-12-01T15:35:00Z Matthew Norawong What they are saying: PASTEUR Act can help fight antimicrobial resistance https://catalyst.phrma.org/what-they-are-saying-pasteur-act-can-help-fight-antimicrobial-resistance <div class="hs-featured-image-wrapper"> <a href="https://catalyst.phrma.org/what-they-are-saying-pasteur-act-can-help-fight-antimicrobial-resistance" title="" class="hs-featured-image-link"> <img src="https://catalyst.phrma.org/hubfs/GettyImages-1168042167resized.jpg" alt="What they are saying: PASTEUR Act can help fight antimicrobial resistance" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"> </a> </div> <p>Antimicrobial resistance (AMR) is a growing health crisis resulting in nearly 50,000 U.S. deaths each year and <a href="https://www.thelancet.com/action/showPdf?pii=S0140-6736%2821%2902724-0">1.27 million</a> globally on an annual basis – higher than HIV/AIDS and malaria. To slow and control continued AMR, we need a robust pipeline of novel products, and at the same time we need to ensure they are used only in a limited set of circumstances and in only the most necessary cases. Without new products to address the problem, AMR globally could take 10 million lives yearly by 2050. Countless modern medical advances that depend on antibiotics—such as routine surgery, cancer therapy and treatment of chronic disease—will be jeopardized if action is not taken now.</p> <div class="hs-featured-image-wrapper"> <a href="https://catalyst.phrma.org/what-they-are-saying-pasteur-act-can-help-fight-antimicrobial-resistance" title="" class="hs-featured-image-link"> <img src="https://catalyst.phrma.org/hubfs/GettyImages-1168042167resized.jpg" alt="What they are saying: PASTEUR Act can help fight antimicrobial resistance" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"> </a> </div> <p>Antimicrobial resistance (AMR) is a growing health crisis resulting in nearly 50,000 U.S. deaths each year and <a href="https://www.thelancet.com/action/showPdf?pii=S0140-6736%2821%2902724-0">1.27 million</a> globally on an annual basis – higher than HIV/AIDS and malaria. To slow and control continued AMR, we need a robust pipeline of novel products, and at the same time we need to ensure they are used only in a limited set of circumstances and in only the most necessary cases. Without new products to address the problem, AMR globally could take 10 million lives yearly by 2050. Countless modern medical advances that depend on antibiotics—such as routine surgery, cancer therapy and treatment of chronic disease—will be jeopardized if action is not taken now.</p> <img src="https://track.hubspot.com/__ptq.gif?a=464546&amp;k=14&amp;r=https%3A%2F%2Fcatalyst.phrma.org%2Fwhat-they-are-saying-pasteur-act-can-help-fight-antimicrobial-resistance&amp;bu=https%253A%252F%252Fcatalyst.phrma.org&amp;bvt=rss" alt="" width="1" height="1" style="min-height:1px!important;width:1px!important;border-width:0!important;margin-top:0!important;margin-bottom:0!important;margin-right:0!important;margin-left:0!important;padding-top:0!important;padding-bottom:0!important;padding-right:0!important;padding-left:0!important; "> Antimicrobial Resistance Wed, 30 Nov 2022 17:00:00 GMT APowaleny@phrma.org (Andrew Powaleny) https://catalyst.phrma.org/what-they-are-saying-pasteur-act-can-help-fight-antimicrobial-resistance 2022-11-30T17:00:00Z Word of the Month: What is TRIPS? https://catalyst.phrma.org/word-of-the-month-what-is-trips <div class="hs-featured-image-wrapper"> <a href="https://catalyst.phrma.org/word-of-the-month-what-is-trips" title="" class="hs-featured-image-link"> <img src="https://catalyst.phrma.org/hubfs/112322_PhRMA_WOTM_BlogThumbnails.jpg" alt="Word of the Month: What is TRIPS?" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"> </a> </div> <p style="font-weight: bold;">What is TRIPS?</p> <div class="hs-featured-image-wrapper"> <a href="https://catalyst.phrma.org/word-of-the-month-what-is-trips" title="" class="hs-featured-image-link"> <img src="https://catalyst.phrma.org/hubfs/112322_PhRMA_WOTM_BlogThumbnails.jpg" alt="Word of the Month: What is TRIPS?" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"> </a> </div> <p style="font-weight: bold;">What is TRIPS?</p> <img src="https://track.hubspot.com/__ptq.gif?a=464546&amp;k=14&amp;r=https%3A%2F%2Fcatalyst.phrma.org%2Fword-of-the-month-what-is-trips&amp;bu=https%253A%252F%252Fcatalyst.phrma.org&amp;bvt=rss" alt="" width="1" height="1" style="min-height:1px!important;width:1px!important;border-width:0!important;margin-top:0!important;margin-bottom:0!important;margin-right:0!important;margin-left:0!important;padding-top:0!important;padding-bottom:0!important;padding-right:0!important;padding-left:0!important; "> Vaccines Coronavirus TRIPS Waiver Word of the Month Tue, 29 Nov 2022 20:55:32 GMT https://catalyst.phrma.org/word-of-the-month-what-is-trips 2022-11-29T20:55:32Z Ernest Kawka and Douglas Petersen Putting Delaware patients first: Protecting Patient Assistance Programs https://catalyst.phrma.org/putting-delaware-patients-first-protecting-patient-assistance-programs <div class="hs-featured-image-wrapper"> <a href="https://catalyst.phrma.org/putting-delaware-patients-first-protecting-patient-assistance-programs" title="" class="hs-featured-image-link"> <img src="https://catalyst.phrma.org/hubfs/IN%20THE%20STATES%20%2850%29.png" alt="Putting Delaware patients first: Protecting Patient Assistance Programs" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"> </a> </div> <p>Patients with chronic health conditions in Delaware are seeing a new wave of relief thanks to Governor John Carney, members of the Delaware legislature and more than 40 patient groups. The recently passed <a href="https://legis.delaware.gov/BillDetail/109376">SB267</a> will make it easier for vulnerable patients to be able to afford their brand medications.</p> <div class="hs-featured-image-wrapper"> <a href="https://catalyst.phrma.org/putting-delaware-patients-first-protecting-patient-assistance-programs" title="" class="hs-featured-image-link"> <img src="https://catalyst.phrma.org/hubfs/IN%20THE%20STATES%20%2850%29.png" alt="Putting Delaware patients first: Protecting Patient Assistance Programs" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"> </a> </div> <p>Patients with chronic health conditions in Delaware are seeing a new wave of relief thanks to Governor John Carney, members of the Delaware legislature and more than 40 patient groups. The recently passed <a href="https://legis.delaware.gov/BillDetail/109376">SB267</a> will make it easier for vulnerable patients to be able to afford their brand medications.</p> <img src="https://track.hubspot.com/__ptq.gif?a=464546&amp;k=14&amp;r=https%3A%2F%2Fcatalyst.phrma.org%2Fputting-delaware-patients-first-protecting-patient-assistance-programs&amp;bu=https%253A%252F%252Fcatalyst.phrma.org&amp;bvt=rss" alt="" width="1" height="1" style="min-height:1px!important;width:1px!important;border-width:0!important;margin-top:0!important;margin-bottom:0!important;margin-right:0!important;margin-left:0!important;padding-top:0!important;padding-bottom:0!important;padding-right:0!important;padding-left:0!important; "> Patient Assistance Programs Out-of-Pocket Costs Tue, 22 Nov 2022 21:05:25 GMT https://catalyst.phrma.org/putting-delaware-patients-first-protecting-patient-assistance-programs 2022-11-22T21:05:25Z Stami Williams How HTA-based price controls could worsen health outcomes and health disparities https://catalyst.phrma.org/how-hta-based-price-controls-could-worsen-health-outcomes-and-health-disparities <div class="hs-featured-image-wrapper"> <a href="https://catalyst.phrma.org/how-hta-based-price-controls-could-worsen-health-outcomes-and-health-disparities" title="" class="hs-featured-image-link"> <img src="https://catalyst.phrma.org/hubfs/Cardiac%20Care%20%2821%29.png" alt="How HTA-based price controls could worsen health outcomes and health disparities" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"> </a> </div> <p><em>Concerns about the cost of health care have led to calls for the use of health technology assessments or HTAs by the federal government. This would allow government agencies to make important decisions about patient access to health care based on their determination of the value of new tests and treatments. In this <a href="https://catalyst.phrma.org/topic/value-assessment">series</a>, we’ll explore how this controversial practice:</em></p> <div class="hs-featured-image-wrapper"> <a href="https://catalyst.phrma.org/how-hta-based-price-controls-could-worsen-health-outcomes-and-health-disparities" title="" class="hs-featured-image-link"> <img src="https://catalyst.phrma.org/hubfs/Cardiac%20Care%20%2821%29.png" alt="How HTA-based price controls could worsen health outcomes and health disparities" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"> </a> </div> <p><em>Concerns about the cost of health care have led to calls for the use of health technology assessments or HTAs by the federal government. This would allow government agencies to make important decisions about patient access to health care based on their determination of the value of new tests and treatments. In this <a href="https://catalyst.phrma.org/topic/value-assessment">series</a>, we’ll explore how this controversial practice:</em></p> <img src="https://track.hubspot.com/__ptq.gif?a=464546&amp;k=14&amp;r=https%3A%2F%2Fcatalyst.phrma.org%2Fhow-hta-based-price-controls-could-worsen-health-outcomes-and-health-disparities&amp;bu=https%253A%252F%252Fcatalyst.phrma.org&amp;bvt=rss" alt="" width="1" height="1" style="min-height:1px!important;width:1px!important;border-width:0!important;margin-top:0!important;margin-bottom:0!important;margin-right:0!important;margin-left:0!important;padding-top:0!important;padding-bottom:0!important;padding-right:0!important;padding-left:0!important; "> Value Assessment Equity Tue, 22 Nov 2022 18:30:00 GMT https://catalyst.phrma.org/how-hta-based-price-controls-could-worsen-health-outcomes-and-health-disparities 2022-11-22T18:30:00Z Katie Koziara The 340B program is interfering with the U.S. biosimilars market and impacting patient costs https://catalyst.phrma.org/the-340b-program-is-interfering-with-the-u.s.-biosimilars-market-and-impacting-patient-costs <div class="hs-featured-image-wrapper"> <a href="https://catalyst.phrma.org/the-340b-program-is-interfering-with-the-u.s.-biosimilars-market-and-impacting-patient-costs" title="" class="hs-featured-image-link"> <img src="https://catalyst.phrma.org/hubfs/Cardiac%20Care%20%2842%29.png" alt="The 340B program is interfering with the U.S. biosimilars market and impacting patient costs" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"> </a> </div> <p>Research has shown that 340B hospitals are more likely to <a href="https://www.milliman.com/en/insight/2020-outpatient-drug-spend-at-340b-hospitals">prescribe more expensive medicines</a> and <a href="https://communityoncology.org/featured/examining-hospital-price-transparency-drug-profits-and-the-340b-program-2022/">significantly mark up the price of medicines</a>. For example, 340B hospitals received nearly five times what they paid, on average, to acquire oncology medicines through 340B. These practices have implications for what patients pay out of pocket — and new research adds to the evidence. A <a href="https://www.milliman.com/en/insight/biosimilar-utilization-at-340b-and-non-340b-outpatient-hospitals-in-the-commercial-market">new Milliman analysis</a> found <span style="font-weight: bold;">340B hospitals have lower utilization of biosimilars than non-340B hospitals</span> among their commercially insured patients, potentially leading to higher out-of-pocket costs for some patients.</p> <div class="hs-featured-image-wrapper"> <a href="https://catalyst.phrma.org/the-340b-program-is-interfering-with-the-u.s.-biosimilars-market-and-impacting-patient-costs" title="" class="hs-featured-image-link"> <img src="https://catalyst.phrma.org/hubfs/Cardiac%20Care%20%2842%29.png" alt="The 340B program is interfering with the U.S. biosimilars market and impacting patient costs" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"> </a> </div> <p>Research has shown that 340B hospitals are more likely to <a href="https://www.milliman.com/en/insight/2020-outpatient-drug-spend-at-340b-hospitals">prescribe more expensive medicines</a> and <a href="https://communityoncology.org/featured/examining-hospital-price-transparency-drug-profits-and-the-340b-program-2022/">significantly mark up the price of medicines</a>. For example, 340B hospitals received nearly five times what they paid, on average, to acquire oncology medicines through 340B. These practices have implications for what patients pay out of pocket — and new research adds to the evidence. A <a href="https://www.milliman.com/en/insight/biosimilar-utilization-at-340b-and-non-340b-outpatient-hospitals-in-the-commercial-market">new Milliman analysis</a> found <span style="font-weight: bold;">340B hospitals have lower utilization of biosimilars than non-340B hospitals</span> among their commercially insured patients, potentially leading to higher out-of-pocket costs for some patients.</p> <img src="https://track.hubspot.com/__ptq.gif?a=464546&amp;k=14&amp;r=https%3A%2F%2Fcatalyst.phrma.org%2Fthe-340b-program-is-interfering-with-the-u.s.-biosimilars-market-and-impacting-patient-costs&amp;bu=https%253A%252F%252Fcatalyst.phrma.org&amp;bvt=rss" alt="" width="1" height="1" style="min-height:1px!important;width:1px!important;border-width:0!important;margin-top:0!important;margin-bottom:0!important;margin-right:0!important;margin-left:0!important;padding-top:0!important;padding-bottom:0!important;padding-right:0!important;padding-left:0!important; "> 340B Biologics and Biosimilars Mon, 21 Nov 2022 18:24:52 GMT NLongo@phrma.org (Nicole Longo) https://catalyst.phrma.org/the-340b-program-is-interfering-with-the-u.s.-biosimilars-market-and-impacting-patient-costs 2022-11-21T18:24:52Z Medicare Part D open enrollment and what recent changes mean for beneficiaries https://catalyst.phrma.org/medicare-part-d-open-enrollment-and-what-recent-changes-mean-for-beneficiaries <div class="hs-featured-image-wrapper"> <a href="https://catalyst.phrma.org/medicare-part-d-open-enrollment-and-what-recent-changes-mean-for-beneficiaries" title="" class="hs-featured-image-link"> <img src="https://catalyst.phrma.org/hubfs/Screen%20Shot%202022-11-17%20at%202.22.09%20PM.png" alt="Medicare Part D open enrollment and what recent changes mean for beneficiaries" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"> </a> </div> <p>It’s that time of year again: <a href="https://www.medicare.gov/plan-compare/#/?year=2023&amp;lang=en">Medicare open enrollment</a>! Seniors and people with disabilities who are newly eligible for Medicare, as well as current Medicare beneficiaries, can select or update their Part D prescription drug plans for 2023 through Wednesday, December 7. Part D beneficiaries have a variety of plans to choose from, ranging from 24 to 32 options in each state. As a result of Part D, nearly 90% of Medicare beneficiaries have comprehensive drug coverage, amounting to more than <a href="https://www.medpac.gov/wp-content/uploads/import_data/scrape_files/docs/default-source/reports/mar21_medpac_report_to_the_congress_sec.pdf">47 million beneficiaries</a> in 2020. But open enrollment can be confusing.</p> <div class="hs-featured-image-wrapper"> <a href="https://catalyst.phrma.org/medicare-part-d-open-enrollment-and-what-recent-changes-mean-for-beneficiaries" title="" class="hs-featured-image-link"> <img src="https://catalyst.phrma.org/hubfs/Screen%20Shot%202022-11-17%20at%202.22.09%20PM.png" alt="Medicare Part D open enrollment and what recent changes mean for beneficiaries" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"> </a> </div> <p>It’s that time of year again: <a href="https://www.medicare.gov/plan-compare/#/?year=2023&amp;lang=en">Medicare open enrollment</a>! Seniors and people with disabilities who are newly eligible for Medicare, as well as current Medicare beneficiaries, can select or update their Part D prescription drug plans for 2023 through Wednesday, December 7. Part D beneficiaries have a variety of plans to choose from, ranging from 24 to 32 options in each state. As a result of Part D, nearly 90% of Medicare beneficiaries have comprehensive drug coverage, amounting to more than <a href="https://www.medpac.gov/wp-content/uploads/import_data/scrape_files/docs/default-source/reports/mar21_medpac_report_to_the_congress_sec.pdf">47 million beneficiaries</a> in 2020. But open enrollment can be confusing.</p> <img src="https://track.hubspot.com/__ptq.gif?a=464546&amp;k=14&amp;r=https%3A%2F%2Fcatalyst.phrma.org%2Fmedicare-part-d-open-enrollment-and-what-recent-changes-mean-for-beneficiaries&amp;bu=https%253A%252F%252Fcatalyst.phrma.org&amp;bvt=rss" alt="" width="1" height="1" style="min-height:1px!important;width:1px!important;border-width:0!important;margin-top:0!important;margin-bottom:0!important;margin-right:0!important;margin-left:0!important;padding-top:0!important;padding-bottom:0!important;padding-right:0!important;padding-left:0!important; "> Health Insurance Part D Medicare Thu, 17 Nov 2022 19:52:18 GMT NLongo@phrma.org (Nicole Longo) https://catalyst.phrma.org/medicare-part-d-open-enrollment-and-what-recent-changes-mean-for-beneficiaries 2022-11-17T19:52:18Z Expanding TRIPS waiver would jeopardize biopharmaceutical research and development https://catalyst.phrma.org/expanding-trips-waiver-would-jeopardize-biopharmaceutical-research-and-development <div class="hs-featured-image-wrapper"> <a href="https://catalyst.phrma.org/expanding-trips-waiver-would-jeopardize-biopharmaceutical-research-and-development" title="" class="hs-featured-image-link"> <img src="https://catalyst.phrma.org/hubfs/Cardiac%20Care%20%2837%29.png" alt="Expanding TRIPS waiver would jeopardize biopharmaceutical research and development" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"> </a> </div> <p>The United States has led the charge in the <a href="https://phrma.org/coronavirus">development of vaccines and treatments to combat COVID-19</a> thanks in large part to our robust innovation ecosystem, supported by intellectual property (IP) protections. The decision made by the Biden Administration and other WTO members earlier this year to waive commitments to protect IP on COVID-19 vaccines under the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement was <a href="https://catalyst.phrma.org/intellectual-property-waiver-on-covid-19-innovation-is-unnecessary-and-harmful">harmful and unnecessary</a> and removed the very incentives that enable scientific advancement. Expanding the TRIPS waiver to include COVID-19 treatments — as some WTO members wish to do — would jeopardize American innovation and our ability to prepare for future pandemics.</p> <div class="hs-featured-image-wrapper"> <a href="https://catalyst.phrma.org/expanding-trips-waiver-would-jeopardize-biopharmaceutical-research-and-development" title="" class="hs-featured-image-link"> <img src="https://catalyst.phrma.org/hubfs/Cardiac%20Care%20%2837%29.png" alt="Expanding TRIPS waiver would jeopardize biopharmaceutical research and development" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"> </a> </div> <p>The United States has led the charge in the <a href="https://phrma.org/coronavirus">development of vaccines and treatments to combat COVID-19</a> thanks in large part to our robust innovation ecosystem, supported by intellectual property (IP) protections. The decision made by the Biden Administration and other WTO members earlier this year to waive commitments to protect IP on COVID-19 vaccines under the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement was <a href="https://catalyst.phrma.org/intellectual-property-waiver-on-covid-19-innovation-is-unnecessary-and-harmful">harmful and unnecessary</a> and removed the very incentives that enable scientific advancement. Expanding the TRIPS waiver to include COVID-19 treatments — as some WTO members wish to do — would jeopardize American innovation and our ability to prepare for future pandemics.</p> <img src="https://track.hubspot.com/__ptq.gif?a=464546&amp;k=14&amp;r=https%3A%2F%2Fcatalyst.phrma.org%2Fexpanding-trips-waiver-would-jeopardize-biopharmaceutical-research-and-development&amp;bu=https%253A%252F%252Fcatalyst.phrma.org&amp;bvt=rss" alt="" width="1" height="1" style="min-height:1px!important;width:1px!important;border-width:0!important;margin-top:0!important;margin-bottom:0!important;margin-right:0!important;margin-left:0!important;padding-top:0!important;padding-bottom:0!important;padding-right:0!important;padding-left:0!important; "> Research and Development Intellectual Property TRIPS Waiver Thu, 17 Nov 2022 15:36:38 GMT https://catalyst.phrma.org/expanding-trips-waiver-would-jeopardize-biopharmaceutical-research-and-development 2022-11-17T15:36:38Z Megan Van Etten Six ways I-MAK is lying about biopharma patents https://catalyst.phrma.org/six-ways-i-mak-is-lying-about-biopharma-patents <div class="hs-featured-image-wrapper"> <a href="https://catalyst.phrma.org/six-ways-i-mak-is-lying-about-biopharma-patents" title="" class="hs-featured-image-link"> <img src="https://catalyst.phrma.org/hubfs/Cardiac%20Care%20%2834%29.png" alt="Six ways I-MAK is lying about biopharma patents" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"> </a> </div> <p>The <a href="https://www.arnoldventures.org/grantees/initiative-for-medicines-access-knowledge-inc">Arnold-Venture funded</a> advocacy group Initiative for Medicines, Access &amp; Knowledge, Inc. (or I-MAK) is on a global media tour, espousing their point of view on the patent system. Some <a href="https://ipwatchdog.com/2022/02/01/tillis-wants-info-mak-data-driving-anti-patent-narratives-around-drug-pricing/id=145105/">experts and congressional leaders</a> don’t buy the rhetoric, and neither should you. Here are the top myths to look out for:</p> <div class="hs-featured-image-wrapper"> <a href="https://catalyst.phrma.org/six-ways-i-mak-is-lying-about-biopharma-patents" title="" class="hs-featured-image-link"> <img src="https://catalyst.phrma.org/hubfs/Cardiac%20Care%20%2834%29.png" alt="Six ways I-MAK is lying about biopharma patents" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"> </a> </div> <p>The <a href="https://www.arnoldventures.org/grantees/initiative-for-medicines-access-knowledge-inc">Arnold-Venture funded</a> advocacy group Initiative for Medicines, Access &amp; Knowledge, Inc. (or I-MAK) is on a global media tour, espousing their point of view on the patent system. Some <a href="https://ipwatchdog.com/2022/02/01/tillis-wants-info-mak-data-driving-anti-patent-narratives-around-drug-pricing/id=145105/">experts and congressional leaders</a> don’t buy the rhetoric, and neither should you. Here are the top myths to look out for:</p> <img src="https://track.hubspot.com/__ptq.gif?a=464546&amp;k=14&amp;r=https%3A%2F%2Fcatalyst.phrma.org%2Fsix-ways-i-mak-is-lying-about-biopharma-patents&amp;bu=https%253A%252F%252Fcatalyst.phrma.org&amp;bvt=rss" alt="" width="1" height="1" style="min-height:1px!important;width:1px!important;border-width:0!important;margin-top:0!important;margin-bottom:0!important;margin-right:0!important;margin-left:0!important;padding-top:0!important;padding-bottom:0!important;padding-right:0!important;padding-left:0!important; "> Patents Intellectual Property Wed, 16 Nov 2022 20:29:35 GMT https://catalyst.phrma.org/six-ways-i-mak-is-lying-about-biopharma-patents 2022-11-16T20:29:35Z Megan Van Etten New data show how insurers and middlemen shift Rx costs onto patients https://catalyst.phrma.org/new-data-show-how-insurers-and-middlemen-shift-rx-costs-onto-patients <div class="hs-featured-image-wrapper"> <a href="https://catalyst.phrma.org/new-data-show-how-insurers-and-middlemen-shift-rx-costs-onto-patients" title="" class="hs-featured-image-link"> <img src="https://catalyst.phrma.org/hubfs/Screen%20Shot%202022-11-16%20at%2010.00.11%20AM.png" alt="New data show how insurers and middlemen shift Rx costs onto patients" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"> </a> </div> <p>There is only one place in the health care system where middlemen refuse to share negotiated prices with patients, and that’s at the pharmacy counter. A <a href="https://phrma.org/resource-center/Topics/Access-to-Medicines/Deductibles-and-Coinsurance-Drive-High-Out-Of-Pocket-Costs-for-Commercially-Insured-Patients-Taking-Brand-Medicines">new report</a> reveals how this harmful tactic leads to higher costs for patients.</p> <div class="hs-featured-image-wrapper"> <a href="https://catalyst.phrma.org/new-data-show-how-insurers-and-middlemen-shift-rx-costs-onto-patients" title="" class="hs-featured-image-link"> <img src="https://catalyst.phrma.org/hubfs/Screen%20Shot%202022-11-16%20at%2010.00.11%20AM.png" alt="New data show how insurers and middlemen shift Rx costs onto patients" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"> </a> </div> <p>There is only one place in the health care system where middlemen refuse to share negotiated prices with patients, and that’s at the pharmacy counter. A <a href="https://phrma.org/resource-center/Topics/Access-to-Medicines/Deductibles-and-Coinsurance-Drive-High-Out-Of-Pocket-Costs-for-Commercially-Insured-Patients-Taking-Brand-Medicines">new report</a> reveals how this harmful tactic leads to higher costs for patients.</p> <img src="https://track.hubspot.com/__ptq.gif?a=464546&amp;k=14&amp;r=https%3A%2F%2Fcatalyst.phrma.org%2Fnew-data-show-how-insurers-and-middlemen-shift-rx-costs-onto-patients&amp;bu=https%253A%252F%252Fcatalyst.phrma.org&amp;bvt=rss" alt="" width="1" height="1" style="min-height:1px!important;width:1px!important;border-width:0!important;margin-top:0!important;margin-bottom:0!important;margin-right:0!important;margin-left:0!important;padding-top:0!important;padding-bottom:0!important;padding-right:0!important;padding-left:0!important; "> Adherence Drug Cost Health Insurance Out-of-Pocket Costs Pharmacy Benefit Managers Wed, 16 Nov 2022 15:26:47 GMT https://catalyst.phrma.org/new-data-show-how-insurers-and-middlemen-shift-rx-costs-onto-patients 2022-11-16T15:26:47Z Brian Newell What you should know about RSV https://catalyst.phrma.org/what-you-should-know-about-rsv <div class="hs-featured-image-wrapper"> <a href="https://catalyst.phrma.org/what-you-should-know-about-rsv" title="" class="hs-featured-image-link"> <img src="https://catalyst.phrma.org/hubfs/Cardiac%20Care%20%2838%29.png" alt="What you should know about RSV" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"> </a> </div> <p>You are probably reading a lot about a surge of cases of respiratory viruses like respiratory syncytial virus (RSV), influenza (the flu) and SARS-CoV-2, which causes COVID-19. The triple threat of these highly contagious respiratory viruses circulating simultaneously is causing a ripple of effects on patients, health care providers and our health care system as a whole.</p> <div class="hs-featured-image-wrapper"> <a href="https://catalyst.phrma.org/what-you-should-know-about-rsv" title="" class="hs-featured-image-link"> <img src="https://catalyst.phrma.org/hubfs/Cardiac%20Care%20%2838%29.png" alt="What you should know about RSV" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"> </a> </div> <p>You are probably reading a lot about a surge of cases of respiratory viruses like respiratory syncytial virus (RSV), influenza (the flu) and SARS-CoV-2, which causes COVID-19. The triple threat of these highly contagious respiratory viruses circulating simultaneously is causing a ripple of effects on patients, health care providers and our health care system as a whole.</p> <img src="https://track.hubspot.com/__ptq.gif?a=464546&amp;k=14&amp;r=https%3A%2F%2Fcatalyst.phrma.org%2Fwhat-you-should-know-about-rsv&amp;bu=https%253A%252F%252Fcatalyst.phrma.org&amp;bvt=rss" alt="" width="1" height="1" style="min-height:1px!important;width:1px!important;border-width:0!important;margin-top:0!important;margin-bottom:0!important;margin-right:0!important;margin-left:0!important;padding-top:0!important;padding-bottom:0!important;padding-right:0!important;padding-left:0!important; "> Vaccines Infectious Diseases Tue, 15 Nov 2022 15:15:26 GMT https://catalyst.phrma.org/what-you-should-know-about-rsv 2022-11-15T15:15:26Z Mike Ybarra